Actively Recruiting
A Study of HS-20124 in Patients with Advanced Solid Tumors
Led by Hansoh BioMedical R&D Company · Updated on 2025-01-08
450
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
HS-20124 is a novel DAR-8 antibody-drug conjugate （ADC） targeting CDH6. In preclinical studies, it inhibited tumor cell growth expressing CDH6 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-20124 in Patients With Advanced Solid Tumors.
CONDITIONS
Official Title
A Study of HS-20124 in Patients with Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years old at screening
- Confirmed locally advanced or metastatic solid tumors without effective or available standard treatment
- At least one measurable tumor lesion outside the brain according to RECIST 1
- ECOG Performance Status of 0 or 1
- Life expectancy of 12 weeks or more
- Using adequate contraception throughout the study
- Female participants must not be pregnant or have evidence of non-childbearing potential
- Signed and dated informed consent form
You will not qualify if you...
- Previous or current treatment targeting CDH6
- Cytotoxic chemotherapy or targeted anticancer drugs within 21 days or five half-lives before first HS-20124 dose
- Monoclonal antibody or investigational agent treatment within 28 days before first HS-20124 dose
- Limited field radiotherapy within 2 weeks, large-scale or bone marrow radiation within 4 weeks before first HS-20124 dose
- Major surgery within 4 weeks before first HS-20124 dose
- Previous or concurrent malignancies other than studied tumors
- Inadequate bone marrow or organ function
- Cardiovascular risk
- Severe or uncontrolled systemic diseases
- Mucosal or internal bleeding within 1 month before first HS-20124 dose
- Severe infection within 4 weeks before first HS-20124 dose
- Current infectious diseases
- History of neuropathy or mental disorders
- Pregnant or breastfeeding females
- History of severe hypersensitivity or infusion reactions to drugs related to HS-20124
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Affiliated Cancer Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 201321
Actively Recruiting
Research Team
X
Xiaohua Wu, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here